Related Experiment Videos
Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma
G F Riedler1, A R Haycox, A K Duggan
1Regionales Blutspendezentrum, Lucerne, Switzerland.
Vox Sanguinis
|August 20, 2003
Summary
Solvent/detergent-treated fresh-frozen plasma (SD-FFP) is cost-effective, particularly for younger patients and those without significant morbidity. Including non-infectious complications reveals SD-FFP
Area of Science:
- Transfusion Medicine
- Health Economics
- Patient Safety
Background:
- Transfusion-transmitted infections are rare, but non-infectious complications are frequent.
- Previous economic evaluations of solvent/detergent-treated fresh-frozen plasma (SD-FFP) underestimated its benefits by not including non-infectious events.
Purpose of the Study:
- To evaluate the cost-effectiveness of SD-FFP compared to untreated fresh-frozen plasma (FFP).
- To incorporate both infectious and non-infectious transfusion-related complications into the economic analysis.
Main Methods:
- A time-series analytical model was employed.
- Cost per life year saved was estimated for SD-FFP versus untreated FFP.
- Analyses controlled for post-transfusion mortality and patient age, considering various complications.
Main Results:
- SD-FFP demonstrated cost-effectiveness, with ratios below key thresholds for younger patient groups.
- Cost-effectiveness varied by age and patient morbidity, with neonates showing favorable ratios.
- Transfusion-related acute lung injury (TRALI) was a significant driver of cost-effectiveness due to its incidence and mortality.
Conclusions:
- Previous cost-effectiveness analyses of SD-FFP were underestimated.
- Including non-infectious complications supports SD-FFP's cost-effectiveness in patients up to 48 years old.
- Wider adoption of SD-FFP may be justified, especially for younger patients and those with good prognoses.